ProShare Advisors
TPST icon

ProShare Advisors’s Tempest Therapeutics TPST Stock Holding History

ProShare Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9
Closed -$182K – 1753
2016
Q3 		$182K Sell
9
-1
-10% -$18.1K ﹤0.01% 1357
2016
Q2 		$154K Buy
10
+2
+25% +$45.7K ﹤0.01% 1471
2016
Q1 		$218K Sell
8
-1
-11% -$21.1K ﹤0.01% 1373
2015
Q4 		$248K Buy
+9
New +$297K ﹤0.01% 1409

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ProShare Advisors's TPST Position: Q4 2016 in Review

ProShare Advisors sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 9 shares — an estimated $182K sold.

ProShare Advisors first reported a position in TPST in Q4 2015 and held it in 4 quarters. The position peaked at $248K in Q4 2015. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

  • ProShare Advisors reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
  • ProShare Advisors sold 9 Tempest Therapeutics shares in Q4 2016, an estimated $182K.
  • ProShare Advisors first reported a position in Tempest Therapeutics in Q4 2015 and held it in 4 quarters.
  • ProShare Advisors's Tempest Therapeutics position peaked at $248K in Q4 2015.
  • 84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on ProShare Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.